[
    {
        "file_name": "ArtaraTherapeuticsInc_20200110_8-K_EX-10.5_11943350_EX-10.5_License Agreement.pdf",
        "perturbation": [
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "3.2 Approval Milestone based on Data Value: Within forty-five (45) days of an approval of the TARA-002 BLA by the FDA, ArTara will pay a one-time approval milestone to University pursuant to the usefulness of the Program Data in TARA-002’s BLA filing, as set forth below:\nOfficial Feedback from FDA regarding the Program Data\nMilestone\n[…***…]\n$[…***…]\n[…***…]\n$[…***…]\n[…***…]\n$[…***…]\n[…***…]\n$[…***…]",
                "changed_text": "3.2 Approval Milestone based on Data Value: Within ninety (90) days of an approval of the TARA-002 BLA by the FDA, ArTara will pay a one-time approval milestone to University pursuant to the usefulness of the Program Data in TARA-002’s BLA filing, as set forth below:\nOfficial Feedback from FDA regarding the Program Data\nMilestone\n[…***…]\n$[…***…]\n[…***…]\n$[…***…]\n[…***…]\n$[…***…]\n[…***…]\n$[…***…]",
                "explanation": "Changing the payment deadline from 45 days to 90 days after BLA approval creates an in-text contradiction. This creates uncertainty as to when the milestone payment is due, potentially leading to disputes.",
                "location": "Section 3.2"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "3.3 Royalties. Royalties will be payable by ArTara on Net Sales of Product in the Indication. ArTara will, no later than […***…] following the close\nof each calendar quarter, pay tiered Royalties based on annual Net Sales of Product in the Indication as set forth below:\nAnnual Net Sales of Product for the\nIndication\nAnnual Royalty Rate Percent Net\nSales\n$0 - $25,000,000\n1.75%\n>$25,000,000 - $50,000,000\n2.25%\n>$50,000,000\n2.50%",
                "changed_text": "3.3 Royalties. Royalties will be payable by ArTara on Net Sales of Product in the Indication. ArTara will, no later than […***…] following the close\nof each calendar month, pay tiered Royalties based on annual Net Sales of Product in the Indication as set forth below:\nAnnual Net Sales of Product for the\nIndication\nAnnual Royalty Rate Percent Net\nSales\n$0 - $25,000,000\n1.75%\n>$25,000,000 - $50,000,000\n2.25%\n>$50,000,000\n2.50%",
                "explanation": "Changing 'calendar quarter' to 'calendar month' for royalty payments introduces a conflict. This creates ambiguity in payment frequency, making it unclear whether royalties should be paid monthly or quarterly.",
                "location": "Section 3.3"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "8.1 Term. This Agreement may be terminated by ArTara upon thirty (30) days prior written notice to University.",
                "changed_text": "8.1 Term. This Agreement may be terminated by ArTara upon sixty (60) days prior written notice to University.",
                "explanation": "Changing the termination notice period from 30 days to 60 days creates an in-text contradiction. It is now unclear which notice period applies for termination, leading to potential legal disputes.",
                "location": "Section 8.1"
            }
        ]
    }
]